Interleukin 23 and autoimmune diseases: current and possible future therapies

Abdo, Ahmad Ismail Khaled; Tye, Gee Jun

doi:10.1007/s00011-020-01339-9

Cited by 29 publications

(18 citation statements)

References 145 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The efficacy of IL-23 blockade was further supported by reduction in IL-17 and IL-22 levels through the sequestration of IL-23 by a decoy protein containing the IL-23 receptor cytokine-binding homology region [84]. Such evidence provides support for potential development of an IL-23 receptor-Fc fusion protein, similar to etanercept [85].…”

Section: Discussionmentioning

confidence: 85%

Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

2020

View full text Add to dashboard Cite

Psoriasis is a common inflammatory skin disease with multiple comorbidities, including psoriatic arthritis and coronary artery disease, that can severely impact an individual’s quality of life and daily functioning. In recent years, enhanced understanding of the pathogenesis of psoriasis, especially the role of T helper 17 cells, has resulted in the development of new classes of biologic drugs targeting modulators along its disease pathway. Among these, inhibitors of interleukin-23 (e.g., ustekinumab, guselkumab, tildrakizumab, and risankizumab) have emerged as safe and effective options for the treatment of moderate-to-severe plaque psoriasis; ustekinumab and guselkumab have additionally been approved to treat psoriatic arthritis. Selective interleukin-23 inhibitors require less frequent dosing than interleukin-17 inhibitors and may possess a more favorable risk profile without an increased risk of candidiasis or inflammatory bowel disease. Overall, these highly effective medications are contributing to a rising standard for psoriasis outcomes through resolution of skin lesions and joint manifestations and improvement of patient quality of life.

show abstract

Section: Discussionmentioning

confidence: 85%

Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review

2020

View full text Add to dashboard Cite

show abstract

“…There are several mAbs targeting cytokines or their receptors developed to reduce inflammatory response in autoimmune disorders. IL-17 as a major cytokine Introduction on Monoclonal Antibodies DOI: http://dx.doi.org/10.5772/intechopen.98378 of Th17 cells, plays crucial roles in immune response against bacterial and fungal infections, as well as in the pathogenesis of autoimmune diseases, importantly in psoriasis [55]. Secukinumab (Cosentyx®), an IgG1 human mAb, binds to IL-17A and is approved for the treatment of psoriasis and ankylosing spondylitis.…”

Section: Other Monoclonal Antibodies For Treating Autoimmune Diseasesmentioning

confidence: 99%

“…IL-23 is also a key proinflammatory cytokine playing an important role in Th-17 differentiation and activation. Guselkumab (Tremfya®), Risankizumab (SKYRIZI®), and Tildrakizumab (Ilumya®) are IgG1 mAbs targeting IL-23 p19 approved for the treatment of patients with plaque psoriasis [55].…”

Section: Other Monoclonal Antibodies For Treating Autoimmune Diseasesmentioning

confidence: 99%

Introduction on Monoclonal Antibodies

Sadeghalvad¹,

Rezaei²

2021

Monoclonal Antibodies

View full text Add to dashboard Cite

Monoclonal antibodies (mAbs) are a group of antibodies produced by identical clones of B lymphocytes against a particular antigen. mAbs are identical in several properties such as protein sequence, antigen-binding site region, binding affinity for their targets, and identical downstream functional effects. These characteristics of mAbs highlight their differences with the polyclonal antibodies which have heterogenous activities and recognize different epitopes on an antigen. Murine mAbs was the first generation of mAbs developed by hybridoma technology however, because of their murine origin, they can trigger the anti-mouse antibody response in the host which could accelerate mAb clearance and undesirable allergic reactions upon repeated administration. This issue was resolved by developing engineering methods toward producing less immunologic chimeric or humanized antibodies. mAbs applications have become a novel way of targeting antigens in a wide variety of diseases such as autoimmunity, malignancies, and asthma. In addition, high specificity and high affinity binding properties of mAbs make them effective biological reagents in immunodiagnostic assays. They can be used in diagnosis of infectious diseases and detection of certain antigens or in serological assessments for detection of antibodies against a certain antigen. This chapter summarizes the general properties of mAbs, their production processes, and their important diagnostic and therapeutic applications.

show abstract

“…Existen diversos elementos compartidos por estas enfermedades, entre los que podemos incluir: la ausencia de un autoantígeno claro que indique la naturaleza autoinmune de estas enfermedades (por ello se prefiere el término «autoinflamatorias»), su profunda relación con la disbiosis intestinal [3][4][5][6] y la participación del eje IL-23/IL-17 en su patogenia [7][8][9][10] . Otro elemento compartido entre estas enfermedades es el fondo genético, en el que se comparten varios polimorfismos de un solo nucleótido (SNP, single nucleotide polymorphism) 2 y la presencia de moléculas de histocompatibilidad como el HLA-B27.…”

Section: Introductionunclassified